초록 ▼

The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine (−)-5, 6, 7, 8-tetrahydro-6-propyl2-(2-thienyl)ethylamino-1-naphtol, containing a matrix for the transdermal administration of rotigotine (−)-5, 6, 7, 8-tetrahydro-6-propyl2-(2-thienyl)ethylamino-1 na

The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine (−)-5, 6, 7, 8-tetrahydro-6-propyl2-(2-thienyl)ethylamino-1-naphtol, containing a matrix for the transdermal administration of rotigotine (−)-5, 6, 7, 8-tetrahydro-6-propyl2-(2-thienyl)ethylamino-1 naphtol, containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 μm, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.

대표청구항 ▼

1. A matrix for transdermal administration of rotigotine that is storage-stable for at least 6 months, the matrix comprising (a) a matrix polymer, and(b) rotigotine base in a concentration above the solubility limit of rotigotine base in the matrix polymer,wherein a portion of the rotigotine base no

1. A matrix for transdermal administration of rotigotine that is storage-stable for at least 6 months, the matrix comprising (a) a matrix polymer, and(b) rotigotine base in a concentration above the solubility limit of rotigotine base in the matrix polymer,wherein a portion of the rotigotine base not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles with a maximum mean diameter of 30 μm, and wherein the matrix is free of solubilizer, crystallization inhibitor and dispersant. 2. A matrix for transdermal administration of rotigotine that is storage-stable for at least 6 months, the matrix consisting of: (a) matrix polymer that is an amine-resistant silicone or a mixture of amine-resistant silicones,(b) rotigotine base in a concentration above the solubility limit of rotigotine base in the matrix polymer, wherein a portion of the rotigotine base not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles with a maximum mean diameter of 30 μm, and(c) optionally one or more antioxidants. 3. The matrix of claim 1, wherein the matrix polymer is an amine-resistant silicone or a mixture of amine-resistant silicones. 4. The matrix of claim 1 or 2 wherein the matrix is self-adhesive. 5. The matrix of claim 1 or 2 wherein the matrix consists of: (a) about 60 to about 95 weight percent of an amine-resistant silicone or an amine-resistant silicone mixture,(b) about 5 to about 40 weight percent amorphous rotigotine base dispersed in the silicone, and(c) zero to about 2 weight percent antioxidant. 6. A system for transdermal administration of rotigotine comprising a matrix of claim 1 or 2 and a backing. 7. The system of claim 6 wherein the backing is impermeable to rotigotine. 8. The system of claim 6 wherein the rotigotine is present in an amount of 0.3 to 6 mg/cm2. 9. The system of claim 6, wherein the rotigotine base is present in an amount permitting a flow rate of rotigotine through human skin that is therapeutically effective, upon application of the system at intervals of 1 to 7 days, for treatment of Morbus Parkinson. 10. The system of claim 6, wherein the rotigotine base is present in an amount permitting a flow rate of rotigotine through human skin that is therapeutically effective, upon application of the system at intervals of 1 to 7 days, for treatment of restless leg syndrome. 11. The system of claim 6, wherein the rotigotine base is present in an amount permitting a flow rate of rotigotine through human skin that is therapeutically effective, upon application of the system at intervals of 1 to 7 days, for treatment of depression.